Literature DB >> 12042200

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.

Doron Gothelf1, Bareket Falk, Pierre Singer, Michal Kairi, Moshe Phillip, Levana Zigel, Irit Poraz, Siegal Frishman, Naama Constantini, Gil Zalsman, Abraham Weizman, Alan Apter.   

Abstract

OBJECTIVE: The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine.
METHOD: The body mass index of male schizophrenic adolescent inpatients treated with olanzapine (N=10) and of 10 matched patients treated with haloperidol (N=10) were measured at baseline and after 4 weeks of treatment. For the patients treated with olanzapine, caloric intake, resting energy expenditure, and physical activity (determined through accelerometry and heart rate monitoring) were assessed at baseline and after 4 weeks of treatment.
RESULTS: Body mass index significantly increased in those treated with olanzapine but not in those given haloperidol. The increase in body mass index was due to an increase in caloric intake without change in diet composition. Olanzapine had no significant effect on resting energy expenditure. Daily energy expenditure was very low before and after treatment.
CONCLUSIONS: Olanzapine-induced weight gain is associated with a general increase in caloric intake.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042200     DOI: 10.1176/appi.ajp.159.6.1055

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  63 in total

Review 1.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

2.  Dietary intake of patients with schizophrenia.

Authors:  Martin Strassnig; Jaspreet Singh Brar; Rohan Ganguli
Journal:  Psychiatry (Edgmont)       Date:  2005-02

3.  A prospective study of serum ghrelin levels in patients treated with clozapine.

Authors:  F M Theisen; S Gebhardt; T Brömel; B Otto; W Heldwein; M Heinzel-Gutenbrunner; J-C Krieg; H Remschmidt; M Tschöp; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

4.  Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.

Authors:  Mikhail Kalinichev; Claire Rourke; Alex J Daniels; Mary K Grizzle; Christy S Britt; Diane M Ignar; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

6.  From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

Authors:  Sangwon F Kim; Alex S Huang; Adele M Snowman; Cory Teuscher; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 7.  The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.

Authors:  C Cuerda; C Velasco; J Merchán-Naranjo; P García-Peris; C Arango
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

8.  Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents.

Authors:  Sun H Kim; Lilla Nikolics; Fahim Abbasi; Cindy Lamendola; James Link; Gerald M Reaven; Steven Lindley
Journal:  J Psychiatr Res       Date:  2009-12-03       Impact factor: 4.791

9.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Authors:  Nima Davoodi; Mikhail Kalinichev; Sergei A Korneev; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

10.  Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

Authors:  Marilyn Ader; W Timothy Garvey; Lawrence S Phillips; Charles B Nemeroff; Georges Gharabawi; Ramy Mahmoud; Andrew Greenspan; Sally A Berry; Dominique L Musselman; Jacqueline Morein; Young Zhu; Lian Mao; Richard N Bergman
Journal:  J Psychiatr Res       Date:  2008-02-25       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.